Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

5,016

Participants

Timeline

Start Date

November 9, 2012

Primary Completion Date

November 25, 2014

Study Completion Date

April 16, 2015

Conditions
RubellaMeaslesMumps
Interventions
BIOLOGICAL

Priorix

Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.

BIOLOGICAL

M-M-R II

Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.

BIOLOGICAL

Varivax

Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.

BIOLOGICAL

Havrix

Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.

BIOLOGICAL

Prevnar 13

US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.

Trial Locations (90)

10117

GSK Investigational Site, Tallinn

10467

GSK Investigational Site, The Bronx

10617

GSK Investigational Site, Tallinn

12004

GSK Investigational Site, Castellon

12530

GSK Investigational Site, Castellon

13210

GSK Investigational Site, Syracuse

13419

GSK Investigational Site, Tallinn

13619

GSK Investigational Site, Tallinn

14850

GSK Investigational Site, Ithaca

16148

GSK Investigational Site, Hermitage

16505

GSK Investigational Site, Erie

18960

GSK Investigational Site, Sellersville

20520

GSK Investigational Site, Turku

21045

GSK Investigational Site, Columbia

22042

GSK Investigational Site, Falls Church

22902

GSK Investigational Site, Charlottesville

23298

GSK Investigational Site, Richmond

28100

GSK Investigational Site, Pori

29812

GSK Investigational Site, Barnwell

33100

GSK Investigational Site, Tampere

34000

GSK Investigational Site, Durango

36305

GSK Investigational Site, Dothan

37660

GSK Investigational Site, Kingsport

40202

GSK Investigational Site, Louisville

44106

GSK Investigational Site, Cleveland

45245

GSK Investigational Site, Cincinnati

46011

GSK Investigational Site, Valencia

46017

GSK Investigational Site, Valencia

46020

GSK Investigational Site, Valencia

46022

GSK Investigational Site, Valencia

46023

GSK Investigational Site, Valencia

46183

GSK Investigational Site, L'Eliana, Valencia

46200

GSK Investigational Site, Valencia

46930

GSK Investigational Site, Quart de Poblet, Valencia

49120

GSK Investigational Site, Niles

49127

GSK Investigational Site, Stevensville

50010

GSK Investigational Site, Ames

50106

GSK Investigational Site, Tartu

53792

GSK Investigational Site, Madison

54449

GSK Investigational Site, Marshfield

60100

GSK Investigational Site, Seinäjoki

60805

GSK Investigational Site, Evergreen Park

64114

GSK Investigational Site, Kansas City

66213

GSK Investigational Site, Overland Park

66604

GSK Investigational Site, Topeka

67010

GSK Investigational Site, Augusta

67100

GSK Investigational Site, Kokkola

71111

GSK Investigational Site, Bossier City

72703

GSK Investigational Site, Fayetteville

76107

GSK Investigational Site, Fort Worth

77070

GSK Investigational Site, Houston

77375

GSK Investigational Site, Tomball

77573

GSK Investigational Site, League City

78229

GSK Investigational Site, San Antonio

80920

GSK Investigational Site, Colorado Springs

80922

GSK Investigational Site, Colorado Springs

83686

GSK Investigational Site, Nampa

84041

GSK Investigational Site, Layton

84067

GSK Investigational Site, Roy

84075

GSK Investigational Site, Syracuse

84088

GSK Investigational Site, West Jordan

84109

GSK Investigational Site, Salt Lake City

84121

GSK Investigational Site, Salt Lake City

84604

GSK Investigational Site, Provo

84651

GSK Investigational Site, Payson

84790

GSK Investigational Site, St. George

85048

GSK Investigational Site, Phoenix

90220

GSK Investigational Site, Oulu

90723

GSK Investigational Site, Paramount

91345

GSK Investigational Site, Mission Hills

92804

GSK Investigational Site, Anaheim

93726

GSK Investigational Site, Fresno

94015

GSK Investigational Site, Daly City

94545

GSK Investigational Site, Hayward

94588

GSK Investigational Site, Pleasanton

94596

GSK Investigational Site, Walnut Creek

95032

GSK Investigational Site, Los Gatos

95051

GSK Investigational Site, Santa Clara

95815

GSK Investigational Site, Sacramento

95823

GSK Investigational Site, Sacramento

98104

GSK Investigational Site, Seattle

02130

GSK Investigational Site, Boston

02721

GSK Investigational Site, Fall River

02886

GSK Investigational Site, Warwick

02230

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

04530

GSK Investigational Site, México

00936-5067

GSK Investigational Site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age | Biotech Hunter | Biotech Hunter